Bacterial Pathogenesis Summary





Patient Overview

10-year-old Ronnie has developed abdominal cramps, bloody diarrhea and <u>a low grade fever</u>. His parents take him to see the family doctor. The doctor asks about what Ronnie has eaten in the past week. His parents recall that last weekend at a neighbor's barbecue they were concerned that the hamburgers may not have been cooked thoroughly and Ronnie ate two burgers. The doctor performs a physical examination noting no rebound tenderness just some mild periumbilical tenderness. He asks the parents to collect a stool sample for the Microbiology Laboratory and also issues a requisition for **routine blood work** (to be performed at the local laboratory). The Microbiology Laboratory report comes back positive for E.coli 0157:H7.

TABLE OF CONTENTS

ENCOUNTER

- Geographical and hose-wise locations
- Bacterial characteristics
- How might the patient have come into contact with it?



ENTRY

Entry into the human host Molecular, cellular, physiological factors



03 MULTIPLICATION & SPREAD

- Extracellular or intracellular?
- Presence of secondary infection sites

04 BACTERIAL DAMAGE

- Direct and indirect damages
- Associated signs and symptoms
- Possible antibiotic treatments

01 ENCOUNTER

Geographical Locations

Within Canada and the U.S.

- More common in western provinces of Canada
- More common in northern states in the U.S.
 - Commonly found in cattles (asymptomatic carriers)
 - Fecal shedding intermittent and seasonal
- can result in a large number of cases due to outbreaks from waterborne or food origin within a community
- sheep, pigs, horses, dogs, deer, and feces of birds may also carry *E. coli* O157:H7



Environmental Locations

- 1. Farms
- 2. Ponds
- 3. Dams
- 4. Wells
- 5. Barns
- 6. Water and water troughs
- 7. Farm equipment
- 8. Ground
- 9. Pasture



ENVIRONMENTAL LOCATIONS

WATER

- Large presence in water due to low temperatures
- Water trough sediments can be contaminated with cattle feces

ANIMAL MOVEMENT

 Animals may come into contact with E. Coli via drinking contaminated water

SOIL

- Survive up to a year in manure-treated soil
- Up to 21 months in raw manure (not composted)

NATURAL EVENTS

• Rainwater, wind can contribute to the spreading and transmission of E. Coli



FLIES

- May encounter contaminated animals
- Transmitted onto food
- Potential effective vectors

PERSISTENCE IN ENVIRONMENT

NUTRIENT-DEFICIENT CONDITIONS

- Can survive up to 10 months in aquatic environments
- Can reduce cell size to allow more efficient nutrient uptake (aka starvation-survival state)
- Activate catabolic enzymes
- Increase production of toxins to kill competitors
- Exopolysaccharide (EPS): heat and acid tolerance
- Lipid membranes can be altered in response to heat stress

NUTRIENT-SUFFICIENT CONDITIONS

 Accumulate reserve carbon sources that are stored for use in nutrient-poor environment

HOST LOCATIONS

01	INTESTINAL CELLULAR WALLS	 Attaches onto the microvilli of intestinal epithelial cells via attaching and effacing (AE) lesions
02	LOW pH ENVIRONMENT IN STOMACH	 Expresses an acid resistance (AR) system, utilizing a rpoS sigma factor and F1F0 ATPase rpoS for better adherence to surfaces and transition of motile cells during environmental stress Other AR mechanisms: decarboxylase and antiporter systems
03	HOST INTESTINE	 upregulates enzymes involved in the catabolism of N-acetylglucosamine, sialic acid, glucosamine, gluconate, arabinose and fucose uses multiple limiting sugars for growth in the intestine and grows using simple sugars released upon breakdown of complex polysaccharides
04	BUTCHERING PROCESS	 Whole cuts of meat only have <i>E. coli</i> on the surface, so easier to kill by cooking grounded meat: <i>E. coli</i> can be transferred to the inside of the meat Ronnie may have come into contact through the contaminated, undercooked, or raw burger meat Can be contaminated via improper handling or hand washing



02 ENTRY



BACTERIAL ENTRY



FOOD TRAVELS DOWN DIGESTIVE TRACT



0

ENTER INTESTINES

CONSUMING

UNCOOKED

FOOD



IN THE STOMACH

- Acid resistance (AR) : allows the organism to survive gastric acidity and volatile fatty acids
- colonize and establish a commensal relationship with mammalian hosts
- Three systems that protect the bacterial cells against pH 2 to 2.5



3 SYSTEM THAT PROTECT E.COLI AGAINST LOW pH

Dependent on the alternative rpoS Sigma Factor sigma factor, encoded by the rpoS gene Requires glutamic acid Consume protons End products, y-aminobutyric acid **Glutamate Dependent Acid** <u>ָ</u> 0 (GABA, formed from glutamate Resistance decarboxylase [GAD]) transported out of the cell via GadC in exchange for the new substrate **Requires arginine** End products, agmatine (formed **Arginine Dependent Acid** from arginine decarboxylase), 2.0. transported out of the cell via Resistance unknown antiporter in exchange for

the new substrate

Glutamate Dependent Acid Resistance





COLANIC ACID SECRETION

- E. coli secretes a variety of EPS, including colanic acid
- E. coli O157:H7 cells are inactivated during acidic conditions due to proton accumulation
- CA serve as a buffer by neutralizing protons at the cell surface
- prevents the positively charged protons from accumulating and penetrating cells
- Without CA, the protons will accumulate and enter the bacteria, causing an imbalance of intracellular charge and ultimately causing cell death

IN THE INTESTINE

GENES	SIGNIFICANCE			
arcA	Bile can cause oxidative stress and result in the damage of DNA and			
arcB	proteins, as well as breaking down the cell membrane of bacterial cells Genes regulate ompF expression and bile efflux to increase two-fold in			
arcR	E. coli 0157:H7 cells			
micF	 Aerobic respiration allows the bacteria to continue providing energy so that it can successfully grow and colonize within the host 			
marB	The bacteria increase mRNA for 17 genes which play a role in the			
marR	acquisition of iron once the bacteria are exposed to bile			

IN THE INTESTINE



- The genes responsible for A/E lesions are due to the locus of enterocyte effacement (LEE)
- The LEE is composed of at least 41 different genes organized into three major regions
 - type III secretion system that exports effector molecules
 - an adhesion called intimin and its translocated receptor, Tir
 - several secreted proteins (Esp) as a part of TTSS
- The Tir protein is also capable of interacting with host cytoskeletal and signalling components

 $\bullet \bullet \bullet$

03 MULTIPLICATION & SPREAD

MULTIPLICATION AND SPREAD

- First location of spread: large intestine
- The pathogen does not only remain extracellularly, but actively invades the intestinal epithelial cells, pumping proteins and toxins into the body's circulatory system
 - Shiga toxins absorbed through the intestinal epithelium
 - Then join the circulatory system
- Disrupt host cell processes
 - Hijacking and altering host cell signaling pathways
 - coordinated host cell invasion
 - evasion of host immune responses
 - efficient colonization
- In animals (eg. cattles), initial colonization of the large intestine often spreads to the rectum.





Shiga toxins Stx1 and Stx2 bind to enterocytes

Pentameric B portion of the Shiga toxin

- binds to the cellular glycolipid receptor globotriaosylceramide (Gb3) and globotriaosylceramide (Gb4)
- Binds to various other cell types:
 - Aortic
 - brain endothelial cells
 - mesangial cells
 - renal tubular and lung epithelial cells
 - cells of the monocytic lineage
 - polymorphonuclear cells
 - Platelets
 - erythrocytes

Monomeric A subunit of the Shiga toxin

- endocytosed into the enterocyte and transported to the rough ER by the Golgi apparatus
- In the TGN, the toxin is cleaved by the enzyme furin into the A1 and A2 subunits
- If toxin was not cleaved by furin, then the cytosolic enzyme caplain may cleave the molecule
- A1 is a glycosidase that hydrolyzes a specific adenine-ribose bond in the ribosomal 28S RNA.
- cleaved ribosomal 28S RNA inhibits protein synthesis, resulting in cell death

Stx induces chemokine synthesis



Increase in toxin receptor expression and breach intestinal

epithelium

Stx enters blood; capillary endothelial cells killed

Activation and aggregation of platelets

initiates leukocyte adherence, cytokine secretion, and vasoconstriction

apoptosis of supporting cells such as inflammatory mediators

Brain + Kidney

- Move across the intestinal epithelium without affecting cell function for further propagation into the circulatory system
- toxin starts to cause damage breaking down red blood cells and the vessels
- In very rare cases does the E. coli continue to
 spread to the brain.

Secondary Pathway

- Shiga toxins causing CXC chemokine production in human endothelium and intestinal mucosal epithelial cells
- promotes intestinal epithelial injury and increased Stx absorption into the systemic circulation by inducing PMN infiltration into the intestinal epithelium

SLOUGHING

Caused by shiga toxins and is a form of bacterial propagation amongst animals

DIARRHEA

Expel a substantial amount of E.coli in the stool

HYGIENE

Ensure infected animals do not contaminate communal apparatuses or expose to other individuals





p0157 plasmid

- Contains the hly operon that encodes enterohemolysin
- This hemolysin allows E. coli O157:H7 to utilize the blood released into the intestine as a source of iron
- Some strains of E. coli 0157:H7 also have EspP
 - cleaves pepsin A and human coagulation factor
 V, contributing to hemorrhage into the intestinal tract
 - cleaves several complement system
 components, protecting the bacteria from
 immune system-mediated elimination

SECONDARY SITES OF INFECTION



COLONIC VASCULAR DAMAGE



- Stx are uptake into resident macrophages and released from dead macrophages to invade the basolateral side of colonocytes
- T3SS effectors cause actin polymerization and ruffle formation and recruit ARP2/3 complex to aid in the process of bacterial entry
- IpaA, VirA, and IpgD: destabilize actin
- IpaB, PiaC, IpaD, and IpaH: escape phagosomes
- IpgD: allow the bacteria to avoid apoptosis
- IpaB: mediate cell cycle rest through the targeting of an inhibitor of anaphase
- MAD2L2 and OspE: prevente epithelial cell attachments via interacting with integrin-linked kinase (ILK)

COLONIC VASCULAR DAMAGE

Four effectors allowing the evasion of innate immune responses

- 1) OspF and IpaH
 - targets the nucleus to irreversibly dephosphorylate protein kinases important for nuclear factor-KB (NF-KB) regulated transcription genes and interferes with the expression of inflammatory cytokines by interacting with splicing factors respectively
- 2) OspG
 - inhibits NF-KB activation
- 3) OspB
 - plays a role in reducing interleukin-8 (IL-8) through recruitment of host factors to help remodel chromatin

Ultimately, it is with these mechanisms that allow the bacteria to persist, survive and maintain infection by reducing the host's inflammatory responses.

INFECTION IN KIDNEY

- Polymorphonuclear leukocytes (PMN) are involved in the spread of Shiga-toxin-related injury by delivering Stx to kidneys
- Damage to the lungs is not as severe as in the kidneys because many kidney cells express the Stx receptor and contain Stx-sensitive cells
- High volume of blood flow and filtration rate of blood in kidneys increases the chance of Stx interaction
- if the renal filtration barrier is damaged, Stx can then interact with tubular epithelial cells of the nephron, leading to further damage
- Globotriaosylceramide (Gb3)
 - acts as the cellular receptor for Stx
 - renal microvascular endothelial cells express a large amount of Gb3
 - expressed by the proximal tubules
- Stx2 has been shown to decrease VEGF production by human podocytes

URINARY TRACT INFECTIONS

- Occur through adhesion to the uroepithelium, in which most adhesins generate separate morphological features termed pili (or fimbriae)
- The adhesion to the uroepithelium is mediated by fimbrial adhesin H (FimH) binding to glycosylated uroplakin Ia in the bladder
- FimH can also bind to alpha-3 and beta-1 integrins at the site of invasion, and destabilization of microtubule can also occur to further assist with invasion into the urinary tract
- Prostatitis in men and pelvic inflammatory disease (PID) in women may be secondary outcomes of UTI's
- Bacteria may eventually reach the bloodstream and make its way further to other tissues of the host





BACTERIAL DAMAGE



Most Escherichia coli (E.coli) strains are harmless.

But some, like enterohemorrhagic E. coli (EHEC), are a hazard to human health and life.

INFECTION SOURCES

Cattle and other ruminants are the main E: coli (EHEC) carriers

Uncooked meat and raw milk

The bacteria die when food is exposed to heat (70⁰C and higher)

Incubation period:

eight days

three to

Fruit and

vegetables (droppings of sick animals find their way into water bodies that in turn feed the soil) E. coli (EHEC), once in the human stomach, begins producing toxins that cause serious illnesses

Symptoms caused by E. coli (EHEC)

- Stomach muscle spasms
- Diarrhea (sometimes bloody diarrhea)
- Fever
- Vomiting

Complications:

hemolytic uremic syndrome (HUS)

```
Death rate: 3-5 %
```

DIRECT DAMAGES

- 1) Shiga toxin causes damage to the intestine by killing cells
- Stx enters enterocytes expressing globotriaosylceramide (Gb3) and globotriaosylceramide (Gb4) via endocytosis
- inhibit protein translation and trigger the ribotoxic and endoplasmic reticulum stress responses
- 4) leads to cell apoptosis through p38 mitogen-activated protein kinase (p38 MAPK) activation and other apoptotic pathways
- 5) leads to the sloughing off of intestinal mucosa cells, which results in hemorrhagic diarrhea
- 6) Shiga toxin also has systemic effects on vascular endothelial cells, resulting in vasculitis, and manifests in HUS, abdominal pain, and in rare cases, thrombotic thrombocytopenic purpura



HOST INFLAMMATORY RESPONSES

- Fever
 - Shiga toxins induce an increase in chemokine synthesis from intestinal epithelial cells
 - release of interleukins, such as IL-8 and IL-1
 - Release of Tumor Necrosis Factor (TNF), as known as pyrogens
 - pyrogens can enter the organum vasculosum of the lamina terminalis (OVLT) within the anterior hypothalamus
 - cells are then stimulated to produce prostaglandin E2 which diffuses into the adjacent preoptic area to upturn the temperature set point and cause fever
- Abdominal tenderness may be more severe if there is hemorrhagic vasculitis
- inflammatory response also leads to
 - leukocyte aggregation
 - apoptosis of the affected cells
 - platelet aggregation
 - microthrombi formation
 - Hemolysis
 - renal dysfunction
 - multiple organ failures in more severe cases

HUS vs. TTP

	Characteristics	Renal damage	Diarrhea	Other damages
Hemolytic Uremic Syndrome (HUS)	Classical triad of microangiopathic hemolytic anemia (fragmented RBCs on blood film), thrombocytopenia, and renal failure	More	More	Neurological abnormalities such as seizures, coma, and hemiparesis
Thrombotic thrombocytopeni a purpura (TTP)	More rare; mainly affects the adult population	Less	Less	

Hemolytic Uremic Syndrome (HUS)



• Children under the age of 5 are particularly susceptible for developing HUS due to a weak immune system

- Additional filtrate load on the glomeruli which become clogged with platelets and damaged red blood cells
- Can lead to kidney failure
- Once the Kidney is severely affected,
 individuals may experience edema,
 albuminuria, decreased urine output,
 hypoalbuminemia and blood in the urine
- Treatment options
 - Hospitalization
 - dialysis in extreme cases
 - Blood transfusions and special diets

HEMOLYTIC UREMIC SYNDROME (HUS)



LIPOPOLYSACCHARIDE (LPS)

- Can damage endothelial cells, increase TNF levels, activate platelets, and induce the blood coagulation cascade
- Can lead to an increased levels of interleukins such as IL-8, which can activate white blood cells (WBCs).
 The host WBCs can then cause damage to the host by producing tissue-damaging enzymes



TREATMENT OPTIONS

- Hydration
- Antibiotics not recommended
 - may trigger an SOS-response and initiate the lytic cycle of bacteriophages
 - May lead to antibiotic-induced injury and release large amounts of toxins
 - lead to more HUS cases as the bacterial motility is decreased
- Antibiotic use is only recommended in cases of sepsis

References

- 1. E. coli [Internet]. Who.int. [cited 2022 Mar 12]. Available from: https://www.who.int/news-room/fact-sheets/detail/e-coli
- 2. Ameer MA, Wasey A, Salen P. Escherichia Coli (E Coli 0157 H7). In: StatPearls [Internet]. StatPearls Publishing; 2021.
- 3. Questions and answers [Internet]. Cdc.gov. 2019 [cited 2022 Mar 12]. Available from: https://www.cdc.gov/ecoli/general/index.html
- 4. Escherichia coli, Diarrheagenic Chapter 4 2020 Yellow Book [Internet]. Cdc.gov. [cited 2022 Mar 12]. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/escherichia-coli-diarrheagenic
- 5. Bach SJ, McAllister TA, Veira DM, Gannon VPJ, Holley RA. Transmission and control of Escherichia coli O157:H7 A review. Can J Anim Sci [Internet]. 2002;82(4):475–90. Available from: http://dx.doi.org/10.4141/a02-021
- 6. Belk KE. Managing pathogen contamination on the farm. In: Improving the Safety of Fresh Meat. Elsevier; 2005. p. 214–27.
- 7. Rahal EA, Kazzi N, Nassar FJ, Matar GM. Escherichia coli O157:H7-Clinical aspects and novel treatment approaches. Front Cell Infect Microbiol [Internet]. 2012;2:138. Available from: http://dx.doi.org/10.3389/fcimb.2012.00138
- 8. Kay KL, Breidt F, Fratamico PM, Baranzoni GM, Kim G-H, Grunden AM, et al. Escherichia coli O157:H7 Acid Sensitivity Correlates with Flocculation Phenotype during Nutrient Limitation. Front Microbiol [Internet]. 2017;8:1404. Available from: http://dx.doi.org/10.3389/fmicb.2017.01404
- 9. Dunn J, Keen J, Thompson R. Prevalence of shiga-toxigenicEscherichia coliO157:H7 in adult dairy cattle. Journal of the American Veterinary Medical Association. 2004;224(7):1151-1158.
- 10. Jiang X, Morgan J, Doyle M. Fate of Escherichia coli O157:H7 in Manure-Amended Soil. Applied and Environmental Microbiology. 2002;68(5):2605-2609.
- 11. LeJeune J, Besser T, Hancock D. Cattle Water Troughs as Reservoirs of Escherichia coli O157. Applied and Environmental Microbiology. 2001;67(7):3053-3057.

12. Jiang X, Morgan J, Doyle MP. Fate of Escherichia coli O157:H7 in manure-amended soil. Appl Environ Microbiol [Internet]. 2002 [cited 2022 Mar 12];68(5):2605–9. Available from: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC127522/

13. Morita R. Bacteria in oligotrophic environments. New York: Chapman & Hall; 1997.

14. Burgess G. Bacteria in Oligotrophic Environments: Starvation Survival Lifestyle. World Journal of Microbiology and Biotechnology. 1997;14(2):305-305.

15. Tao H, Bausch C, Richmond C, Blattner F, Conway T. Functional Genomics: Expression Analysis of Escherichia coli Growing on Minimal and Rich Media. Journal of Bacteriology. 1999;181(20):6425-6440.

16. Miller J, Mekalanos J, Falkow S. Coordinate Regulation and Sensory Transduction in the Control of Bacterial Virulence. Science. 1989;243(4893):916-922.

17. Martín J. Phosphate Control of the Biosynthesis of Antibiotics and Other Secondary Metabolites Is Mediated by the PhoR-PhoP System: an Unfinished Story. Journal of Bacteriology. 2004;186(16):5197-5201.

18. Siegele D, Kolter R. Life after log. Journal of Bacteriology. 1992;174(2):345-348.

19. Chang DE, Smalley DJ, Tucker DL, Leatham MP, Norris WE, Stevenson SJ, Anderson AB, Grissom JE, Laux DC, Cohen PS, et al. Carbon nutrition of Escherichia coli in the mouse intestine. Proc Natl Acad Sci U S A. 2004;101:7427–7432

20. Fabich AJ, Jones SA, Chowdhury FZ, Cernosek A, Anderson A, Smalley D, McHargue JW, Hightower GA, Smith JT, Autieri SM, et al. Comparison of carbon nutrition for pathogenic and commensal Escherichia coli strains in the mouse intestine. Infect Immun. 2008;76:1143–1152.

21. Martens EC, Roth R, Heuser JE, Gordon JI. Coordinate regulation of glycan degradation and polysaccharide capsule biosynthesis by a prominent human gut symbiont. J Biol Chem. 2009;284:18445–18457.

22. HealthLink BC. E. coli Infection. BC Center for Disease Control. 2022. Retrieved 16 March 2022, from <u>https://www.healthlinkbc.ca/healthlinkbc-files/e-coli-infection</u>

23. Castanie-Cornet M-P, Penfound TA, Smith D, Elliott JF, Foster JW. Control of acid resistance in Escherichia coli. J Bacteriol [Internet]. 1999 [cited 2022 Mar 17];181(11):3525–35. Available from: https://pubmed.ncbi.nlm.nih.gov/10348866/

24. Jordan KN, Oxford L, O'Byrne CP. Survival of low-pH stress by Escherichia coli O157:H7: correlation between alterations in the cell envelope and increased acid tolerance. Appl Environ Microbiol [Internet]. 1999 [cited 2022 Mar 17];65(7):3048–55. Available from: https://pubmed.ncbi.nlm.nih.gov/10388702/

25. Hamner S, McInnerney K, Williamson K, Franklin MJ, Ford TE. Bile salts affect expression of Escherichia coli O157:H7 genes for virulence and iron acquisition, and promote growth under iron limiting conditions. PLoS One [Internet]. 2013 [cited 2022 Mar 17];8(9):e74647. Available from: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3769235/

26. Lim JY, Yoon J, Hovde CJ. A brief overview of Escherichia coli O157:H7 and its plasmid O157. J Microbiol Biotechnol [Internet]. 2010 [cited 2022 Mar 17];20(1):5–14. Available from: <u>https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3645889/</u>

27. DeVinney R, Stein M, Reinscheid D, Abe A, Ruschkowski S, Finlay BB. Enterohemorrhagic Escherichia coli O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated. Infect Immun [Internet]. 1999 [cited 2022 Mar 17];67(5):2389–98. Available from: <u>https://pubmed.ncbi.nlm.nih.gov/10225900/</u>

28. McWilliams BD, Torres AG. Enterohemorrhagic Escherichia coli adhesins. Microbiol Spectr [Internet]. 2014 [cited 2022 Mar 17];2(3). Available from: <u>https://pubmed.ncbi.nlm.nih.gov/26103974/</u>

29. Luo Y, Frey EA, Pfuetzner RA, Creagh AL, Knoechel DG, Haynes CA, et al. Crystal structure of enteropathogenic Escherichia coli intimin-receptor complex. Nature [Internet]. 2000 [cited 2022 Mar 18];405(6790):1073–7. Available from: <u>https://www.nature.com/articles/35016618</u>

30. Nataro J.P., Bopp C.S., Fields P.I. Escherichia, Shigella, and Salmonella. In: Murray P.R., Baron E.J., Jorgensen J.H., editors. Manual of clinical microbiology. 9th edition. American Society for Microbiology; Washington, DC: 2007. pp. 670–687.

31. Ameer MA, Wasey A, Salen P. Escherichia Coli (E Coli 0157 H7) [Updated 2021 Dec 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507845/

32. Rahal EA, Kazzi N, Nassar FJ, Matar GM. Escherichia coli O157: H7—Clinical aspects and novel treatment approaches. Frontiers in Cellular and Infection Microbiology. 2012 Nov 15;2:138.

33. Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins. 2020; 12(2):67. <u>https://doi.org/10.3390/toxins12020067</u>

34. El-Radhi A. S. (2019). Pathogenesis of Fever. Clinical Manual of Fever in Children, 53–68. https://doi.org/10.1007/978-3-319-92336-9_3

35. Raji MA, Jiwa SF, Minga MU, Gwakisa PS. Escherichia coli 0157: H7 reservoir, transmission, diagnosis and the African situation: a review. East Afr Med J. 2003 May;80(5):271-6.

36. Gianantonio CA. Hemolytic uremic syndrome. Acute Renal Failure. 1984;327–39.

37. Nauschuetz, W. Emerging foodborne pathogens: enterohemorrhagic Escherichia coli. Clin. Lab. Sci. 1998; 11:298–304.

38. Siegler, R. L. The hemolytic uremic syndrome. Pediatr. Clin. North Am. 1995; 42: 1505–1529.

39. Melton-Celsa A., Shiga Toxin (Stx) Classification, Structure, and Function. American Society For Microbiology. 2014.; Available from: https://journals.asm.org/doi/10.1128/microbiolspec.EHEC-0024-2013

40. Hemolytic Uremic Syndrome (HUS). National Kidney Foundation. 2015.; Available from: https://www.kidney.org/atoz/content/hemolytic

41. Hemolytic Uremic Syndrome in Children. National Institute of Diabetes and Digestive and Kidney Diseases. 2015.; Available from: https://www.niddk.nih.gov/health-information/kidney-disease/children/hemolytic-uremic-syndrome

42. Meyers KEC, Kaplan BS. Many cell types are shiga toxin targets. Kidney International. 2000;57(6):2650–1.



THANK YOU!